Loading quotes...
Forecast
The analysts' average price target is €11.76 (+168.49%). The median is €10.74 (+145.21%).
| Buy |
14 |
| Hold |
19 |
| Sell |
4 |
News Go to news feed
Court backs X in trademark dispute, allows Bluebird to keep bird logo and "to tweet"
A Delaware court preliminarily found that X (formerly Twitter) is likely to retain the trademark rights in a later main proceeding, and in doing so has already protected the company against further infringements. At the same time, the start-up Bluebird may continue to use its feathered logo and the verb "to tweet" for sending messages. Judge Colm Connolly justified the injunction by saying Bluebird infringed and diluted the marks, but the court sees signs that X stopped earlier use. The main trademark trial will decide the final rights. » More on faz.net
Financials
| (EUR) | March 2025 | |
|---|---|---|
| Revenue | 35.78M | - |
| Gross profit | 24.47M | - |
| Net profit | -26.87M | - |
| EBITDA | -7.1M | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €41.82M |
Number of shares | 9.79M |
52-week high/low | €24.57 - €2.75 |
| Dividends | No |
Beta | 0.37 |
P/E ratio | -0.20 |
PEG ratio | 0.00 |
P/B ratio | -1.53 |
P/S ratio | 0.58 |
Company profile
| Name | Bluebird Bio Aktie |
| CEO | Andrew Obenshain |
| Employees | 248 |
Discover assets
Shareholders of Bluebird Bio Aktie also invest in the following assets